Research Assistant at Stansberry Research, Elizabeth Piper remotely interviewed Senior Analyst, Dave Lashmet who disclosed information on a recent announcement that the FDA made pertaining to the biggest medical discovery in the longest time. This in turn is believed to shake up the biotech industry in a positive way. To be more precise, Dave is believed to possess the name and ticker symbol of the drugmaker whose drug has just been approved by the FDA.
In speaking with Elizabeth, Dave confirmed that he not only identified one major company that is set to watch its stock prices skyrocket but four, all of which are trusted to start a “whole new wave of medicine.” Deemed companies almost 100 times smaller than the likes of Pfizer and Abbott, Dave’s picks may possibly climb as high as 1,000%. For those of you who are wondering what the supposed disease that Dave is referring to entails, it is none other than obesity.
Today, there exist many solutions that affirm the use of natural ingredients to fight off obesity, however, such claims often lack scientific evidence. Moreover, they are neither regulated nor approved by the FDA. With close to 42% of U.S. adults reported as being clinically obese and likely to be diagnosed with one of 70 different diseases, the FDA’s recent approval is certain to have the entire weight management industry shaken.
All things considered, the company that got the FDA to approve their drug managed to develop a solution that is believed to:
- Prevent the body from storing excessive amounts of fat
- Mimic the effects of increased metabolism
- Heal the scars that flourished because of high levels of fat deposits
- Repair and revamp an overworked liver to a normally functioning one
As for the three other companies, they have the potential to cure fatty liver disease. His selection is well-thought-out seeing that liver damage has been linked to obesity. With the general information provided so far, individuals are likely to wonder how they can secure investments in said pharmaceutical companies. Well, to get in on what Dave Lashmet has in terms of research, a membership to Stansberry Venture Technology will need to be purchased first.
What is Stansberry Venture Technology?
Stansberry Venture Technology is a monthly research advisory that dives into diverse, small-cap companies within the medical drug and/or technology sectors. For someone with a strong track record in both technology and biotechnology, seeing Dave Lashmet lead this service is reassuring to a large extent.
Throughout his career, he’s managed to invent three active patents and conceptualized, developed, and later sold innovative ideas to some of the largest firms across the world. Most of all, Dave is one of the first employees to have helped shape Stansberry Research since 1999. In fact, his expertise was well reflected between the years, 1999 and 2006, as Dave’s recommendations led to a maximum of 322% gains for his subscribers, making it one of the top ten best-returning positions witnessed by the research firm. Other winners include Intuitive Surgical, Autonomy, and Illumina.
Regarding Stansberry Venture Technology’s portfolio snapshot, members can anticipate holding anywhere between 15 to 25 positions in a year’s time, most of which are deemed speculative. The typical holding period for this service is between 12 months and three years, hence, it is highly unlikely that Dave will put short trades. Similarly, this service seems most apt for investors with large initial investments.
What does a membership to Stansberry Venture Technology give access to?
Once individuals become a member of Stansberry Venture Technology, Dave Lashmet’s team will unlock access to a report called, “The Triple Play: Three 1000% Obesity Drug Companies.” Inside this report, members can begin to familiarize themselves with three companies that are working on viable treatments for obesity and fatty liver disease. Specifically, the names and ticker symbols, the science behind the effectiveness of the drugs, when Dave trusts the FDA will approve the three companies’ drugs, and other educational pieces of information will be summarized. In addition, two bonus reports will be made available as well. These include:
Bonus #1. A New Type of Energy Company With 500% Gain Potential
In this report, Dave will go over the details of one particular energy company deemed an expert in the use of geothermal technology. He strongly believes that with time this tiny company alone can result in 500% in gains.
Bonus #2. The Universal Cancer Cure
As hinted in the title, Dave hopes the second bonus will educate members on the latest breakthroughs regarding cancer cures. In it, he will also list the names and ticker symbols of the picks he is most excited about. In fact, he asserts that they could return several hundred in gains (percentage) in the years to come.
As for the basic incentives of becoming a member of Stansberry Venture Technology, they include:
12 Monthly Venture Technology Issues where Dave will provide concise explanations on the latest trends in venture investing
- Access to Special Readers-Only Reports, which serve as in-depth guides on incredible opportunities
- Access to The Stansberry Digest, where the editorial team will keep members in the loop (Monday through Friday) on interesting situations and new ideas taking shape in the markets
- Access to the Venture Technology Handbook covering Dave’s investing philosophy
How much does a membership to Stansberry Venture Technology cost?
A one-year membership to Stansberry Venture Technology is $2,500, which has been reduced from an original price of $5,500. Bear in mind that once the first year is up, a charge for the same amount will be made thereafter. Should Dave’s recommendations fail to impress, customer service can be contacted for full credit. This could be used to sign up for other memberships offered by Stansberry Research. To learn more about the offer at hand as well as the process of getting credited, contact customer service in the following ways:
- Call: 1 (888) 261-2693
- Email: firstname.lastname@example.org
- Address: Stansberry Research, LLC. 1125 N Charles St, Baltimore MD 21201.
Stansberry Venture Technology Final Verdict
Ultimately, Dave Lashmet is hopeful that the most recent breakthrough in the pharmaceutical industry can finally attack a dominating health concern across the world, i.e., obesity. As mentioned earlier in this piece, he believes that four small companies are on the brink of fully launching their solutions, one of which has already attained approval from the FDA, while the three remaining companies are trusted to follow suit.
That said, this service might not be suitable for people who would prefer a conservative investment strategy. Moreover, the official website suggests a minimum investment of $50,000, which is no small amount. As a final remark, we ask that everyone reflect on their respective financial positions and investment goals prior to placing an order to Stansberry Venture Technology. To find out more about Stansberry Venture Technology, visit here>>>.
More Like This: Crypto Swap Profits Mastermind Reviews – Is Joel Peterson Legit?
The links contained in this product review may result in a small commission if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products.
Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease.